Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006;25:293
   PubMed Web of Science ®Google Scholar
• Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005;95:335-40
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-63
   PubMed Web of Science ®Google Scholar
• Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004;171:752-6
   PubMed Web of Science ®Google Scholar
• Preik M, Albrecht D, O'Connell M, et al. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. BJU Int 2004;94:821-7
   PubMed Web of Science ®Google Scholar
• Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 2006;22:41-8
   PubMed Web of Science ®Google Scholar
• Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002;18:177-84
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
   PubMed Web of Science ®Google Scholar
• Karram MM, Toglia MR, Serels SR, et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009;73:14-18
   PubMed Web of Science ®Google Scholar
• Toglia MR, Serels SR, Laramee C, et al. Solifenacin treatment in patients with overactive bladder improves patient-reported outcomes in the VESIcare efficacy and safety in patients with urgency study (VENUS). Obst Gynecol 2009; In press
   Google Scholar
• Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005;174:604-7
   PubMed Web of Science ®Google Scholar
• Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005;95:591-6
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005;14:849-55
   PubMed Web of Science ®Google Scholar
• Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94
   PubMed Web of Science ®Google Scholar
• Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 2008;62:925-31
   PubMed Web of Science ®Google Scholar
• Abrams P, Artibani W, Gajewski JB, et al. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68:17-28
   PubMed Web of Science ®Google Scholar
• Freeman RM. How urgent is urgency? A review of current methods of assessment. Int Urogynecol J Pelvic Floor Dysfunct 2005;16:93-5
   PubMed Web of Science ®Google Scholar
• Starkman JS, Dmochowski RR. Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn 2008;27:13-21
   PubMed Web of Science ®Google Scholar